A Phase II, Open-labeled, Randomised, Non-comparative, Two-arms Investigator-initiated Clinical Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib in Subjects With Advanced Triple Negative Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 21 Oct 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Jun 2020.
- 17 Sep 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Sep 2019.
- 04 Jun 2019 Results (data cut off: 30 Jan 2019; n=34) assessing efficacy and safety of SHR-1210 combined with apatinib in patients with breast cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology